FDA Restarts Rulemaking To Establish Criteria For "Waived" CLIA Status
This article was originally published in The Gray Sheet
FDA's Division for Clinical Laboratory Devices is planning to hold a public meeting this fall to discuss proposed criteria for categorizing laboratory tests as "waived" from Clinical Laboratory Improvement Act requirements, staffers report.
You may also be interested in...
FDA will take the lead in reviewing Clinical Laboratory Improvement Act waiver applications and protocols, as well as complexity categorizations, starting Nov. 1.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.